Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity, Safety and Immunogenicity of a Live Monovalent А/17/Hong Kong/2017/75108 (H7N9) Influenza Vaccine

NCT03739229 is registered in ClinicalTrials.gov with Research Institute of Influenza, Russia as lead sponsor.

NCT NCT03739229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity, Safety and Immunogenicity of a Live Monovalent А/17/Hong Kong/2017/75108 (H7N9) Influenza Vaccine
Lead sponsor
Research Institute of Influenza, Russia
Phase
Phase 1
Overall status
Unknown status
Start date
December 3, 2018
Completion date
July 3, 2019
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

vaccine adverse reaction